A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of
selected patients with indolent lymphoma. The efficacy endpoints are:
- the rate of complete and partial responses
- the time to progression.
Secondary Objectives:
- To evaluate the safety and tolerability of autologous tumor-derived heat-shock protein
peptide complex (HSPPC-96) administered intradermally once weekly for four consecutive
weeks, followed by HSPPC-96 administered once every two weeks.
- To evaluate the feasibility of autologous HSPPC-96 preparation from lymphoma specimens.
- To assess approximately the composition of the tissue source of the autologous HSPPC-96
for each patient.
- To study the effect of autologous lymphoma-derived HSPPC-96 vaccine therapy on the
expression of Fas ligand and TRAIL death proteins in peripheral blood lymphocytes of
patients with indolent lymphoma.